China's National Leader in Gynecologic Oncology
The Department of Gynecologic Oncology at Fudan University Obstetrics and Gynecology Hospital (Red House Hospital / 红房子医院) — affiliated with Fudan University — is widely recognized as one of China's premier gynecologic oncology centers, with a national reputation for excellence in the surgical and medical management of cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer, and gestational trophoblastic disease. As one of China's highest-volume gynecologic oncology programs, the department combines outstanding surgical expertise with a world-class research program and access to the latest targeted therapies, immunotherapy, and PARP inhibitors, offering international patients access to some of China's most eminent gynecologic oncologists. China Medical Concierge Shanghai (CMCS) provides seamless end-to-end coordination for international patients throughout their gynecologic cancer care journey.
About the Department
The gynecologic oncology department is a national key clinical specialty operating dedicated oncology wards, multiple robotic and laparoscopic operating theaters (da Vinci Xi), a gynecologic oncology outpatient clinic, a chemotherapy and immunotherapy day unit, a molecular diagnostics laboratory, a clinical trials unit, and works in close collaboration with radiation oncology, medical oncology, pathology, and reproductive medicine through a fully integrated multidisciplinary gynecologic tumor board.
Faculty members publish regularly in leading gynecologic oncology journals including Journal of Clinical Oncology, Gynecologic Oncology, International Journal of Gynecological Cancer, Annals of Oncology, and Lancet Oncology.
Cervical Cancer
Surgical Treatment
- Radical Hysterectomy — Robotic-assisted radical hysterectomy (RARH) for early-stage cervical cancer (IA2-IB1); laparoscopic radical hysterectomy; open radical hysterectomy for IB2-IIA; Querleu-Morrow classification (type B, C1, C2); pelvic lymph node dissection; sentinel lymph node biopsy (SLN); one of China's highest-volume radical hysterectomy programs
- Fertility-Sparing Surgery — Radical trachelectomy (vaginal, abdominal, robotic) for stage IA1-IB1 tumors ≤2cm; cervical conization for microinvasive disease; SLN mapping; one of China's most experienced fertility-sparing cervical cancer programs
- Minimally Invasive Surgery — Robotic radical hysterectomy; laparoscopic radical hysterectomy; LACC trial considerations; patient selection for MIS vs. open; protective vaginal manipulator techniques
- Pelvic Exenteration — Anterior, posterior, and total pelvic exenteration for recurrent cervical cancer; urinary diversion; colostomy; reconstruction; one of China's most experienced pelvic exenteration programs
- Para-aortic Lymph Node Dissection — Laparoscopic staging para-aortic lymphadenectomy before chemoradiation for locally advanced disease
Medical Treatment
- Concurrent Chemoradiation (CCRT) — Cisplatin-based CCRT for locally advanced cervical cancer (IB3-IVA); coordination with radiation oncology; brachytherapy (IGBT — image-guided brachytherapy)
- Immunotherapy — Pembrolizumab + chemotherapy ± bevacizumab for persistent/recurrent/metastatic cervical cancer (KEYNOTE-826); cemiplimab + chemotherapy (EMPOWER-Cervical 1); nivolumab; sintilimab
- Targeted Therapy — Bevacizumab + chemotherapy (GOG 240); tisotumab vedotin (TV — innovaTV 301) for recurrent cervical cancer; pembrolizumab for MSI-H/TMB-high
- Neoadjuvant Chemotherapy — Paclitaxel + cisplatin/carboplatin before surgery for selected IB2-IIA2 cases; downstaging for fertility preservation
Endometrial Cancer
Surgical Treatment
- Robotic & Laparoscopic Hysterectomy — Robotic-assisted total hysterectomy + bilateral salpingo-oophorectomy (BSO) + pelvic lymph node dissection; one of China's highest-volume robotic endometrial cancer surgery programs; LAP2 trial evidence for MIS equivalence
- Sentinel Lymph Node Mapping — ICG fluorescence-guided SLN mapping; replacing systematic lymphadenectomy for low-risk disease; FIRES trial evidence; robotic fluorescence imaging
- Fertility-Sparing Treatment — Progestin therapy (medroxyprogesterone acetate, megestrol acetate) for grade 1 endometrioid endometrial cancer confined to endometrium in young women; hysteroscopic resection + progestin; LNG-IUD; one of China's most experienced fertility-sparing endometrial cancer programs
- Staging Surgery — Omentectomy for high-grade histologies; para-aortic lymphadenectomy for high-risk disease; peritoneal washings; appendectomy for mucinous histology
Medical Treatment
- Immunotherapy — Pembrolizumab + lenvatinib for MSS/pMMR recurrent endometrial cancer (KEYNOTE-775); dostarlimab for dMMR/MSI-H (GARNET); pembrolizumab for dMMR/MSI-H; durvalumab + chemotherapy (DUO-E); pembrolizumab + chemotherapy (KEYNOTE-868)
- Targeted Therapy — Lenvatinib + pembrolizumab; everolimus + letrozole for ER-positive; selinexor for p53-mutated; trastuzumab deruxtecan (T-DXd) for HER2-positive uterine serous carcinoma; inavolisib for PIK3CA-mutated
- Molecular Classification — POLE ultramutated; MMR-deficient (dMMR/MSI-H); p53-mutated (serous-like); NSMP (no specific molecular profile); ProMisE and TCGA classification; treatment stratification by molecular subtype
- Hormonal Therapy — Progestins; aromatase inhibitors; tamoxifen for ER-positive recurrent disease
Ovarian Cancer
Surgical Treatment
- Primary Debulking Surgery (PDS) — Complete cytoreduction (R0) as primary goal; total abdominal hysterectomy + BSO + omentectomy + pelvic and para-aortic lymphadenectomy + peritoneal stripping; bowel resection; diaphragm stripping; splenectomy; one of China's most experienced ovarian cancer debulking programs
- Interval Debulking Surgery (IDS) — After 3 cycles of neoadjuvant chemotherapy for stage IIIC-IV disease; CHORUS and EORTC 55971 evidence; complete cytoreduction goal
- Fertility-Sparing Surgery — Unilateral salpingo-oophorectomy for stage IA grade 1-2 epithelial ovarian cancer; borderline ovarian tumors; germ cell tumors; sex cord-stromal tumors in young women
- Secondary Cytoreduction — For platinum-sensitive recurrence; DESKTOP III and SOC-1 trial evidence; patient selection (AGO score, iMODEL)
- HIPEC — Hyperthermic intraperitoneal chemotherapy at interval debulking; cisplatin-based; van Driel trial evidence; one of China's most experienced HIPEC programs
Medical Treatment
- First-Line Chemotherapy — Carboplatin + paclitaxel; dose-dense weekly paclitaxel (JGOG 3016); carboplatin + paclitaxel + bevacizumab (GOG 218, ICON7); carboplatin + paclitaxel + bevacizumab + olaparib (PAOLA-1 for HRD-positive)
- PARP Inhibitors (Maintenance) — Olaparib for BRCA1/2-mutated (SOLO-1); niraparib for all-comers (PRIMA); rucaparib; veliparib; olaparib + bevacizumab for HRD-positive (PAOLA-1); one of China's most experienced PARP inhibitor programs
- Recurrent Ovarian Cancer — Platinum-sensitive: carboplatin + paclitaxel/gemcitabine/PLD + bevacizumab; PARP inhibitor maintenance after response; mirvetuximab soravtansine (SORAYA/MIRASOL) for FRα-high platinum-resistant; bevacizumab for platinum-resistant; weekly paclitaxel; topotecan
- HRD Testing — BRCA1/2 germline and somatic testing; HRD score (Myriad myChoice, Foundation Medicine); genomic instability score; LOH; TAI; LST; guides PARP inhibitor selection
- Immunotherapy — Pembrolizumab for MSI-H/dMMR ovarian cancer; dostarlimab; clinical trial access for novel combinations
Vulvar & Vaginal Cancer
- Vulvar Cancer Surgery — Wide local excision; radical vulvectomy; inguinofemoral lymphadenectomy; SLN biopsy for early-stage; reconstruction with flaps; one of China's most experienced vulvar cancer programs
- Vaginal Cancer — Radiation therapy; brachytherapy; surgery for selected cases; coordination with radiation oncology
- VIN & VAIN — Imiquimod; laser ablation; surgical excision; sinecatechins
Gestational Trophoblastic Disease (GTD)
- Hydatidiform Mole — Suction curettage; hCG surveillance; prophylactic chemotherapy for high-risk mole
- Gestational Trophoblastic Neoplasia (GTN) — Low-risk GTN: single-agent methotrexate or actinomycin D; high-risk GTN: EMA-CO; ultra-high-risk: EMA-EP; placental site trophoblastic tumor (PSTT): surgery; epithelioid trophoblastic tumor (ETT): surgery; one of China's most experienced GTD programs
- Resistant GTN — BEP; TP/TE; pembrolizumab for PD-L1-positive resistant GTN; avelumab
Why International Patients Choose Fudan University OB/GYN Hospital Gynecologic Oncology
- China's National Leader — One of China's highest-volume gynecologic oncology programs; unparalleled surgical expertise across all gynecologic cancers
- Mirvetuximab Soravtansine — FRα-targeted ADC for platinum-resistant high-grade serous ovarian cancer; SORAYA and MIRASOL trial evidence
- Tisotumab Vedotin — Tissue factor-targeted ADC for recurrent cervical cancer; innovaTV 301 evidence
- Fertility-Sparing Expertise — One of China's most experienced fertility-sparing programs for cervical, endometrial, and ovarian cancer
- HIPEC Program — One of China's most experienced HIPEC programs for ovarian cancer at interval debulking
- Molecular Classification — TCGA/ProMisE endometrial cancer molecular classification; treatment stratification by POLE, dMMR, p53, NSMP subtypes
- Cost-Effectiveness — World-class gynecologic oncology care at significantly lower cost than equivalent treatment in Western countries
The CMCS Patient Journey
- Initial Inquiry — Share your gynecologic cancer diagnosis, pathology reports, molecular profiling results, imaging (CT, MRI, PET-CT), and prior treatment history with CMCS.
- Medical Record Preparation — We translate and organize your records for specialist pre-consultation review.
- Specialist Matching — We identify the most appropriate gynecologic oncologist based on your cancer type — cervical, endometrial, ovarian, vulvar, or gestational trophoblastic disease.
- MDT Submission — We facilitate pre-arrival case review by the multidisciplinary gynecologic tumor board.
- Priority Scheduling — We secure a consultation with minimal waiting time.
- Travel & Logistics — Assistance with visa invitation letters, accommodation near Fudan University OB/GYN Hospital, and Shanghai airport transfers.
- Surgical & Treatment Coordination — Full coordination of robotic or laparoscopic surgical admission, chemotherapy scheduling, and PARP inhibitor initiation.
- Post-Treatment Follow-Up — Surgical report translation, pathology result interpretation, maintenance therapy coordination, and remote follow-up after you return home.
Book a Consultation
If you have cervical cancer, endometrial cancer, ovarian cancer, vulvar cancer, gestational trophoblastic disease, or any gynecologic malignancy — CMCS can arrange a specialist consultation with Fudan University OB/GYN Hospital's gynecologic oncology team in Shanghai.
📧 contract@medicalsh.com
💬 WhatsApp: https://wa.me/message/3AM6KAGCW2BAD1
🌐 www.medicalsh.com
댓글 0개